Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Waynac-TBR
- Development stage
- Unknown
- Lead developer
- SBM Enterprises
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
Waynac-TBR is a fixed-dose combination pharmaceutical product marketed by SBM Enterprises, primarily used for its anti-inflammatory and analgesic properties. It contains **aceclofenac**, a non-steroidal anti-inflammatory drug (NSAID), in combination with the proteolytic enzymes **trypsin** and **bromelain**, and the flavonoid **rutoside**. Aceclofenac provides pain relief by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of inflammatory prostaglandins. Trypsin and bromelain facilitate the breakdown of inflammatory by-products and fibrin, aiding in the resolution of edema and promoting tissue healing. Rutoside serves as an antioxidant and vasoprotective agent, helping to maintain capillary integrity and reduce permeability. This formulation is typically indicated for the treatment of pain and swelling associated with musculoskeletal disorders, trauma, or post-operative recovery.
- Brand names
- Waynac-TBR
- Other names
- Aceclofenac + Trypsin + Bromelain + Rutoside
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Waynac-TBR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Waynac-TBR.